Navigation Links
BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
Date:8/20/2008

WOBURN, Mass., Aug. 20 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted BioVex's Clinical Trial Application to conduct a Phase I clinical study testing the safety and immunogenicity of its lead infectious disease candidate for genital herpes, ImmunoVEX HSV2.

ImmunoVEX HSV2 is a novel live-attenuated vaccine which has been rationally designed to remove the genes that allow herpes virus to avoid the immune system. This should allow the immune system to recognize and mount a powerful immune response against the causative agent of genital herpes. In preclinical studies, ImmunoVEX HSV2 completely prevented all symptoms of genital herpes and triggered a powerful immune response, suggesting that ImmunoVEX HSV2 may be more potent than other HSV-2 vaccines for which data has been published.

BioVex's Founder and Chief Technology Officer, Dr. Robert Coffin, commented:

"Genital herpes is a significant and growing public health issue. All previous attempts to develop either a prophylactic or therapeutic vaccine have either failed or have shown efficacy in only a very limited proportion of the population. We believe that this vaccine, based on a new understanding of HSV biology, has the potential to substantially advance the field. Accordingly, today's news is a significant milestone towards realizing this potential."

About Genital Herpes

At least 45 million people over the age of 12 in the United States have been infected with HSV-2, the cause of genital herpes, according to the Centers for Disease Control and Prevention. There is currently no cure for genital herpes and the standard treatment protocol includes daily suppressive therapy and antiviral medications.

About BioVex

BioVex is a privately held biotechnology Company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEXGM-CSF is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEXGM-CSF works by: replicating and spreading within solid tumors, causing the death of cancer cells; while stimulating the immune system to destroy metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. BioVex believes OncoVEXGM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data generated to date, coupled with a benign side effect profile.

BioVex is currently completing a Phase II clinical trial of OncoVEXGM-CSF for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Earlier this year, the Company announced that the FDA approved the design of a single, pivotal Phase III clinical trial evaluating OncoVEXGM-CSF in previously treated patients with metastatic melanoma under the Special Protocol Assessment (SPA) procedure and plans to make a second SPA submission for head & neck cancer later in the year. BioVex intends to begin its Phase III trial for OncoVEXGM-CSF in melanoma in the first quarter of 2009.

For further information, please go to http://www.biovex.com.


'/>"/>
SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
2. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
3. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
4. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
5. Clinical Trials Bootcamp Announces Inaugural Meeting
6. Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
7. NewCardio Announces Positive Results From Third Clinical Validation Study
8. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
9. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
10. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
11. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016 Quantum Radiology,s Mobile ... expert radiologist interpretation directly to women at the workplace, ... corporations, such as Delta Air Lines and SunTrust Bank, ... as a component of wellness initiatives. "I ... SunTrust. It enables them to have a mammogram without ...
(Date:12/2/2016)... , December 2, 2016 ... Awards Committee honored excellence in research, development and innovation ... The gala dinner was held in the presence of ... the Russian Federation , Natalia Sanina, ... Mikhail Murashko , Head of Roszdravnadzor, National Service ...
(Date:12/2/2016)... 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), today ... Inc. ("PSI").  The combination of Texas -based ... -based PSI bring together both company,s clinical expertise and high-touch ... an industry-leading specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of the print ... to practice medicine at an early age by his father, who was also a ... prescribing medicine,” he states. “It is about building relationships with people; relationships that are ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( ... day and night. No other wearable health technology on the market can deliver all ... give poeple more meaningful insights about their health than the usual heart rate and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today ... intelligent, connected applications, was named the best Sales Team of 2016 as part ... was made today by the Software & Information Industry Association (SIIA), the principal ...
(Date:11/30/2016)... ... ... "I hate when the mixture of saliva and toothpaste runs down my ... Bridgewater, N.J. "I thought that there had to be a way to prevent this ... DEFLECTOR to prevent saliva and toothpaste from running down the brush handle onto the ...
Breaking Medicine News(10 mins):